List view / Grid view
Thermo Fisher Scientific Inc.,the world leader in serving science, announced that the United States Pharmacopeial Convention (USP) has selected its Thermo Scientific TruScan RM and microPHAZIR RX instruments to support its recent initiative to provide USP-approved libraries to pharmaceutical manufacturers.
14 January 2013 | By Pfizer
Quillivant XR™ CII for extended-release oral suspension is now available...
11 January 2013 | By Johnson & Johnson
Janssen announced that the EC has approved an extension to the license of the oral, once-daily medication ZYTIGA®...
11 January 2013 | By Merck
Merck is taking steps to suspend the availability of TREDAPTIVE™ tablets worldwide...
11 January 2013 | By H. Lundbeck A/S
The move strengthens the company's capacity to bring drugs to market effectively...
11 January 2013 | By Novartis
Data published today...
10 January 2013 | By Sirius Analytical Instruments Ltd
Sirius Analytical Instruments Ltd announces the introduction of a new product...
10 January 2013 | By Catalent Pharma Solutions
The investment will focus on expanding pMDI clinical and commercial supply capabilities...
An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes.1 Time is a critical factor in diagnosing and treating people who may be having a potential heart attack. To aid physicians in detecting heart attacks sooner, Abbott announced today CE Marking (Conformité…
9 January 2013 | By GlaxoSmithKline
GSK and Theravance announced the submission of a regulatory application...
9 January 2013 | By B&W Tek, Inc.
B&W Tek, Inc., announces Dr. Katherine Bakeev as the new Director of Analytical Services and Support...
8 January 2013 | By Daiichi Sankyo
Daiichi Sankyo & Amplimmune have entered into a broad strategic collaboration...
8 January 2013 | By Sanofi
Sanofi will provide an update on its Research & Development (R&D) pipeline...
8 January 2013 | By Abbott
Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States...
Lonza today announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years.
